Literature DB >> 11251878

New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs.

L Nitschke1, H Floyd, P R Crocker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251878     DOI: 10.1046/j.1365-3083.2001.00868.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


× No keyword cloud information.
  5 in total

Review 1.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

2.  The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound.

Authors:  Soerge Kelm; Judith Gerlach; Reinhard Brossmer; Claus-Peter Danzer; Lars Nitschke
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

3.  Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.

Authors:  Natalia V Giltiay; Geraldine L Shu; Anthony Shock; Edward A Clark
Journal:  Arthritis Res Ther       Date:  2017-05-15       Impact factor: 5.156

Review 4.  Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Authors:  John Daly; Mattias Carlsten; Michael O'Dwyer
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

5.  Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity.

Authors:  Rebecca A Kohnz; Lindsay S Roberts; David DeTomaso; Lara Bideyan; Peter Yan; Sourav Bandyopadhyay; Andrei Goga; Nir Yosef; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2016-07-22       Impact factor: 5.100

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.